Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022116 (
ischemia
)
91,303
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The 14-3-3 protein family comprises critical regulatory molecules involved in signaling during cell division, proliferation, and apoptosis. Despite extensive study, the functions of the 14-3-3 proteins in brain remain unclear. 14-3-3gamma, a subtype of the 14-3-3 family of proteins, was thought to be brain- and neuron-specific. Using RNA arbitrarily primed PCR, we identified an upregulated cDNA fragment of the 14-3-3gamma gene in primary cultures of astrocytes. Using Northern blot analysis, we confirmed this fragment was brain-specific. In cultures of astrocytes, 14-3-3gamma genes and proteins were differentially expressed at different ages and the proteins were distributed only in the cytoplasm. These results indicated that 14-3-3gamma was not neuron-specific but also expressed in astrocytes. The function of this protein in brain is unclear. Northern and Western blot analyses demonstrated that 14-3-3gamma mRNA and protein were upregulated in cultured astrocytes in an anaerobic chamber-induced
ischemia
model. The induction of 14-3-3gamma proteins was neither suppressed by an MAP kinase inhibitor (U0126) nor a PI-3 kinase inhibitor (LY294002). These data indicated that induction of 14-3-3gamma might not involve PI-3 and MAP kinase-dependent pathways. Using coimmunoprecipitation, we demonstrated that endogenous 14-3-3gamma bound to c-Raf-1 and p-Raf 259. As Raf is one of the critical
serine
/threonine kinases controlling cell growth, differentiation, and death, the binding of 14-3-3gamma to Raf indicates the critical role of this protein in
ischemia
-induced apoptosis and the changes in signal transduction in astrocytes in culture.
...
PMID:14-3-3gamma is upregulated by in vitro ischemia and binds to protein kinase Raf in primary cultures of astrocytes. 1273 Sep 52
Ischemia
-reperfusion injury is a major complication occurring in acute myocardial infarction, cardiopulmonary bypass surgery, and heart transplantation. The aim of this study was to identify proteins that were involved in
ischemia
-reperfusion injury using fluorescence two-dimensional difference gel electrophoresis. We compared the 100,000 x g precipitate fractions of normal, ischemic and
ischemia
-reperfused rat hearts and detected six spots which changed more than two-fold in expression level and two additional spots related to these spots. Using peptide mass fingerprinting by matrix-assisted laser desorption/ionization-time of flight mass spectrometry, we identified five of these spots as protein disulfide isomerase A3 (PDA3), one as 60 kDa heat shock protein (HSP60) and two as elongation factor Tu (EF-Tu). HSP60 was increased during
ischemia
and decreased to normal expression level after reperfusion. EF-Tu was increased in
ischemia
but not decreased by reperfusion. We also found that several protein spots of PDA3 shifted towards a higher isoelectric point in
ischemia
and
ischemia
-reperfusion. Our data strongly suggested that PDA3 underwent dephosphorylation during
ischemia
and reperfusion and
serine
343 of PDA3 was one of the phosphorylation sites.
...
PMID:Proteomic analysis of rat heart in ischemia and ischemia-reperfusion using fluorescence two-dimensional difference gel electrophoresis. 1287 33
The interaction between translocated calcium/calmdulin-dependent protein kinase IIalpha (CaMK IIalpha) and SynGAP during brain
ischemia
was investigated by Western blotting and immunoprecipitation. Brain
ischemia
was induced by the four-vessel occlusion method on Sprague-Dawley rats. After 3 min global
ischemia
, both the binding of CaMK IIalpha to SynGAP and the
serine
phosphorylation of SynGAP all dramatically increased. Administrating KN-62 through cerebral ventricle (20 min before
ischemia
) not only remarkably decreased the binding of CaMK IIalpha to SynGAP but also attenuate the elevated
serine
phosphorylation of SynGAP following 20 min
ischemia
in hippocampus. These results suggest that CaMK IIalpha is responsible for the
serine
phosphorylation of SynGAP and a consequent phosphorylation and inhibition of SynGAP may result in activation of mitogen-activated protein kinase pathway which could serve a protective function in brain
ischemia
.
...
PMID:Cerebral ischemia immediately increases serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP by calcium/calmodulin-dependent protein kinase II alpha in hippocampus of rats. 1295 Nov 99
Secretory leukocyte protease inhibitor (SLPI) is a 12-kDa secreted protein initially identified from epithelial cells as an inhibitor of leukocyte
serine
proteases. In the present study, we described the identification of SLPI expression in ischemic cortex by suppression subtractive hybridization strategy. Our full-length rat SLPI cDNA shares 81% and 63% amino acid sequence identity with its mouse and human homologs, respectively, and with several polymorphisms to previous reported rat sequences. Northern blot analysis confirmed that SLPI mRNA was significantly induced in the ischemic brain tissue at 12 h (5.1-fold increase over sham controls, n = 4, p < 0.05), peaked at 2 days (26.1-fold increase, p < 0.001), and sustained up to 5 days (5.1-fold increase, p < 0.05). SLPI was localized in neurons and astrocytes in the peri-infarct zone from 24 to 72 h after middle cerebral artery occlusion by means of immunohistochemical and confocal microscopy analysis. Administration of a recombinant adenovirus overexpressing SLPI (Adv/SLPI) into the cortical tissue resulted in up to 58.4% reduction in ischemic lesion over controls at the site of Adv/SLPI expression (p < 0.01, n = 8) and significantly improved functional outcome (p < 0.01). These data suggest that the
ischemia
-induced expression of SLPI might play a neuroprotective role in focal stroke, possibly because of rapid inhibition of activated proteases and its suppression in inflammatory response.
...
PMID:Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: adenoviral expression of SLPI protects brain from ischemic injury. 1450 Jul 39
The
serine
proteases tissue plasminogen activator, plasmin, and thrombin and their receptors have previously been suggested to contribute to neuronal damage in certain pathological situations. Here we demonstrate that mice lacking protease-activated receptor 1 (PAR1) have a 3.1-fold reduction in infarct volume after transient focal cerebral ischemia. Intracerebroventricular injection of PAR1 antagonist BMS-200261 reduced infarct volume 2.7-fold. There are no detectable differences between PAR1-/- and WT mice in cerebrovascular anatomy, capillary density, or capillary diameter, demonstrating that the neuroprotective phenotype is not likely related to congenital abnormalities in vascular development. We also show that the exogenously applied
serine
proteases thrombin, plasmin, and tissue plasminogen activator can activate PAR1 signaling in brain tissue. These data together suggest that if blood-derived
serine
proteases that enter brain tissue in ischemic situations can activate PAR1, this sequence of events may contribute to the harmful effects observed. Furthermore, PAR1 immunoreactivity is present in human brain, suggesting that inhibition of PAR1 may provide a novel potential therapeutic strategy for decreasing neuronal damage associated with
ischemia
and blood-brain barrier breakdown.
...
PMID:The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. 1455 73
The solute carrier family 1 (SLC1) is composed of five high affinity glutamate transporters, which exhibit the properties of the previously described system XAG-, as well as two Na+-dependent neutral amino acid transporters with characteristics of the so-called "ASC" (alanine,
serine
and cysteine). The SLC1 family members are structurally similar, with almost identical hydropathy profiles and predicted membrane topologies. The transporters have eight transmembrane domains and a structure reminiscent of a pore loop between the seventh and eighth domains [Neuron 21 (1998) 623]. However, each of these transporters exhibits distinct functional properties. Glutamate transporters mediate transport of L-Glu, L-Asp and D-Asp, accompanied by the cotransport of 3 Na+ and one 1 H+, and the countertransport of 1 K+, whereas ASC transporters mediate Na+-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr. Given the high concentrating capacity provided by the unique ion coupling pattern of glutamate transporters, they play crucial roles in protecting neurons against glutamate excitotoxicity in the central nervous system (CNS). The regulation and manipulation of their function is a critical issue in the pathogenesis and treatment of CNS disorders involving glutamate excitotoxicity. Loss of function of the glial glutamate transporter GLT1 (SLC1A2) has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS), resulting in damage of adjacent motor neurons. The importance of glial glutamate transporters in protecting neurons from extracellular glutamate was further demonstrated in studies of the slc1A2 glutamate transporter knockout mouse. The findings suggest that therapeutic upregulation of GLT1 may be beneficial in a variety of pathological conditions. Selective inhibition of the neuronal glutamate transporter EAAC1 (SLC1A1) but not the glial glutamate transporters may be of therapeutic interest, allowing blockage of glutamate exit from neurons due to "reversed glutamate transport" of EAAC1, which will occur during pathological conditions, such as during
ischemia
after a stroke.
...
PMID:The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. 1461 54
Recent evidence suggests that impaired insulin/insulin-like growth factor I (IGF-I) input may be associated to neurodegeneration. Several major neurodegenerative diseases involve excitotoxic cell injury whereby excess glutamate signaling leads to neuronal death. Recently it was shown that glutamate inactivates Akt, a
serine
-kinase crucially involved in the prosurvival actions of IGF-I. We now report that excitotoxic doses of glutamate antagonize Akt activation by IGF-I and inhibit the neuroprotective effects of this growth factor on cultured neurons. Glutamate induces loss of sensitivity to IGF-I by phosphorylating the IGF-I receptor docking protein insulin-receptor-substrate (IRS)-1 in Ser(307) through a pathway involving activation of PKA and PKC in a hierarchical fashion. Administration of Ro320432, a selective PKC inhibitor, abrogates the inhibitory effects of glutamate on IGF-I-induced Akt activation in vitro and in vivo and is sufficient to block the neurotoxic action of glutamate on cultured neurons. Notably, administration of Ro320432 after ischemic insult, a major form of excitotoxic injury in vivo, results in a marked decrease ( approximately 50%) in infarct size. Therefore, uncoupling of IGF-I signaling by glutamate may constitute an additional route contributing to excitotoxic neuronal injury. Further work should determine the potential use of PKC inhibitors as a novel therapeutic strategy in
ischemia
and other excitotoxic insults.
...
PMID:Glutamate excitotoxicity attenuates insulin-like growth factor-I prosurvival signaling. 1469 66
Ebselen, a selenium-containing heterocyclic compound, prevents
ischemia
-induced cell death. However, the molecular mechanism through which ebselen exerts its cytoprotective effect remains to be elucidated. Using sodium nitroprusside (SNP) as a nitric oxide (NO) donor, we show here that ebselen potently inhibits NO-induced apoptosis of differentiated PC12 cells. This was associated with inhibition of NO-induced phosphatidyl
Serine
exposure, cytochrome c release, and caspase-3 activation by ebselen. Analysis of key apoptotic regulators during NO-induced apoptosis of differentiated PC12 cells showed that ebselen blocks the activation of the apoptosis signaling-regulating kinase 1 (ASK1), and inhibits phosphorylation of p38 mitogen-activated protein kinase (MAPK) and c-jun N-terminal protein kinase (JNK). Moreover, ebselen inhibits NO-induced p53 phosphorylation at Ser15 and c-Jun phosphorylation at Ser63 and Ser73. It appears that inhibition of p38 MAPK and p53 phosphorylation by ebselen occurs via a thiol-redox-dependent mechanism. Interestingly, ebselen also activates p44/42 MAPK, and inhibits the downregulation of the antiapoptotic protein Bcl-2 in SNP-treated PC12 cells. Together, these findings suggest that ebselen protects neuronal cells from NO cytotoxicity by reciprocally regulating the apoptotic and antiapoptotic signaling cascades.
...
PMID:Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-2. 1471 91
The author reported that sodium orthovanadate rescues cells from delayed neuronal death in gerbil hippocampus after transient forebrain
ischemia
though phosphatidylinositol 3 kinase/Akt pathway. We here demonstrated that the activation of FKHR, a Forkhead transcription factor and a substrate for Akt, precedes the delayed neuronal death in CA1 regions after transient forebrain
ischemia
. The phosphorylation of FKHR at
serine
-256 in the CA1 region decreased immediately after reperfusion. The dephosphorylation of FKHR was correlated with the decreased Akt activity. Intracerebroventricular injection of orthovanadate 30 min before
ischemia
inhibited dephosphorylation of FKHR after reperfusion, and block delayed neuronal death in the CA1 regions. Two days after reperfusion, expression of Fas ligand increased in the CA1 region and the orthovanadate injection inhibited this increased expression. Furthermore, sublethal
ischemia
gradually and persistently stimulated the phosphorylation of Akt-Ser-473 in the CA1 region after reperfusion. The preceded sublethal
ischemia
prevented the delayed neuronal death induced by the lethal ischemic conditions. Intracerebroventricular injection of wortmannin before preconditioning blocked both the increased in Akt-Ser-473 phosphorylation and the neuroprotective action of preconditioning. These results suggested that the inactivation of Akt results in the activation of FKHR and, in turn, relates to the expression of Fas ligand in the hippocampal CA1 region after transient forebrain
ischemia
. The prevention of Akt inactivation by treatment with orthovanadate is a potential therapeutic strategy for neuroprotection in brain ischemic insult. Thus PI3-kinase/Akt pathway and its downstream molecules are potential targets for drug development in the brain ischemic insult.
...
PMID:[Signal transduction and development of drug for brain ischemic insult]. 1472 12
Recent study has indicated that postsynaptic density protein 95 (PSD95) promotes Ca2+/calmodulin-dependent protein kinase II (CaMKII)-mediated
serine
phosphorylation of neuronal nitric oxide synthase (nNOS). To investigate whether PSD95 is involved in the brain
ischemia
-induced enhancement of
serine
phosphorylation of nNOS by CaMKII in rat hippocampus, we examined the interactions among CaMKIIalpha, PSD95 and nNOS, and the effects of suppression of PSD95 expression on both the increased
serine
phosphorylation of nNOS and the interactions mentioned above by immunoprecipitation and immunoblotting. The following results were observed: (1) brain
ischemia
increased markedly the interactions of CaMKIIalpha and nNOS with PSD95. (2) Intracerebroventricular infusion of PSD95 antisense oligodeoxynucleotides, but not missense oligodeoxynucleotides or vehicle, not only significantly decreased the protein level of PSD95 but also attenuated the elevated
serine
phosphorylation of nNOS and the interactions among CaMKIIalpha, PSD95 and nNOS induced by 15 min
ischemia
. These data suggested that PSD95 is important for facilitating nNOS
serine
phosphorylation by CaMKII.
...
PMID:Postsynaptic density protein 95 mediates Ca2+/calmodulin-dependent protein kinase II-activated serine phosphorylation of neuronal nitric oxide synthase during brain ischemia in rat hippocampus. 1473 65
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>